These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 19737946)

  • 21. C-kit, GIST, and imatinib.
    Siehl J; Thiel E
    Recent Results Cancer Res; 2007; 176():145-51. PubMed ID: 17607922
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
    Garner AP; Gozgit JM; Anjum R; Vodala S; Schrock A; Zhou T; Serrano C; Eilers G; Zhu M; Ketzer J; Wardwell S; Ning Y; Song Y; Kohlmann A; Wang F; Clackson T; Heinrich MC; Fletcher JA; Bauer S; Rivera VM
    Clin Cancer Res; 2014 Nov; 20(22):5745-5755. PubMed ID: 25239608
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase 2 study of nilotinib as third-line therapy for patients with gastrointestinal stromal tumor.
    Sawaki A; Nishida T; Doi T; Yamada Y; Komatsu Y; Kanda T; Kakeji Y; Onozawa Y; Yamasaki M; Ohtsu A
    Cancer; 2011 Oct; 117(20):4633-41. PubMed ID: 21456006
    [TBL] [Abstract][Full Text] [Related]  

  • 24. The heat shock protein 90 inhibitor IPI-504 induces KIT degradation, tumor shrinkage, and cell proliferation arrest in xenograft models of gastrointestinal stromal tumors.
    Floris G; Debiec-Rychter M; Wozniak A; Stefan C; Normant E; Faa G; Machiels K; Vanleeuw U; Sciot R; Schöffski P
    Mol Cancer Ther; 2011 Oct; 10(10):1897-908. PubMed ID: 21825009
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Advanced gastrointestinal stromal tumor in Europe: a review of updated treatment recommendations.
    Blay JY; Reichardt P
    Expert Rev Anticancer Ther; 2009 Jun; 9(6):831-8. PubMed ID: 19496720
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Patterns of care, prognosis, and survival in patients with metastatic gastrointestinal stromal tumors (GIST) refractory to first-line imatinib and second-line sunitinib.
    Italiano A; Cioffi A; Coco P; Maki RG; Schöffski P; Rutkowski P; Le Cesne A; Duffaud F; Adenis A; Isambert N; Bompas E; Blay JY; Casali P; Keohan ML; Toulmonde M; Antonescu CR; Debiec-Rychter M; Coindre JM; Bui B
    Ann Surg Oncol; 2012 May; 19(5):1551-9. PubMed ID: 22065192
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Second line therapies for the treatment of gastrointestinal stromal tumor.
    Joensuu H
    Curr Opin Oncol; 2007 Jul; 19(4):353-8. PubMed ID: 17545799
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Developments in targeted therapy of advanced gastrointestinal stromal tumors.
    Rutkowski P; Symonides M; Zdzienicki M; Siedlecki JA
    Recent Pat Anticancer Drug Discov; 2008 Jun; 3(2):88-99. PubMed ID: 18537751
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Secondary mutation of c-kit/PDGFRα genotypes after imatinib mesylate therapy and its relationship with efficacy of sunitinib].
    Hong JL; Li J; Li J; Shen L
    Zhonghua Bing Li Xue Za Zhi; 2012 Jun; 41(6):386-90. PubMed ID: 22932406
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Gastrointestinal stromal tumors.
    Antonescu C
    Curr Top Microbiol Immunol; 2012; 355():41-57. PubMed ID: 22015552
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
    Reichardt P; Blay JY; Gelderblom H; Schlemmer M; Demetri GD; Bui-Nguyen B; McArthur GA; Yazji S; Hsu Y; Galetic I; Rutkowski P
    Ann Oncol; 2012 Jul; 23(7):1680-7. PubMed ID: 22357255
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.
    Prenen H; Cools J; Mentens N; Folens C; Sciot R; Schöffski P; Van Oosterom A; Marynen P; Debiec-Rychter M
    Clin Cancer Res; 2006 Apr; 12(8):2622-7. PubMed ID: 16638875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Nilotinib is effective in imatinib and sunitinib resistant GIST: a case report.
    Dizdar O; Yalcin S
    Hepatogastroenterology; 2011; 58(107-108):859-60. PubMed ID: 21830404
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sunitinib for imatinib-resistant GIST.
    Joensuu H
    Lancet; 2006 Oct; 368(9544):1303-4. PubMed ID: 17046443
    [No Abstract]   [Full Text] [Related]  

  • 35. Neoadjuvant use of sunitinib in locally advanced GIST with intolerance to imatinib.
    Svetlichnaya J; Huyck TK; Wayne JD; Agulnik M
    Chemotherapy; 2012; 58(1):30-3. PubMed ID: 22415035
    [TBL] [Abstract][Full Text] [Related]  

  • 36. KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients.
    Gajiwala KS; Wu JC; Christensen J; Deshmukh GD; Diehl W; DiNitto JP; English JM; Greig MJ; He YA; Jacques SL; Lunney EA; McTigue M; Molina D; Quenzer T; Wells PA; Yu X; Zhang Y; Zou A; Emmett MR; Marshall AG; Zhang HM; Demetri GD
    Proc Natl Acad Sci U S A; 2009 Feb; 106(5):1542-7. PubMed ID: 19164557
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Evidence-based treatment of gastrointestinal stromal tumor (GIST) with tyrosine kinase inhibitors-imatinib and sunitinib].
    Nishida T; Omori T; Ueshima S
    Gan To Kagaku Ryoho; 2011 May; 38(5):733-7. PubMed ID: 21566432
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Imatinib plus low-dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high-dose imatinib: a phase I-II study by the Spanish Group for Research on Sarcomas.
    Maurel J; Martins AS; Poveda A; López-Guerrero JA; Cubedo R; Casado A; Martínez-Trufero J; Ramón Ayuso J; Lopez-Pousa A; Garcia-Albeniz X; Garcia del Muro X; de Alava E
    Cancer; 2010 Aug; 116(15):3692-701. PubMed ID: 20564079
    [TBL] [Abstract][Full Text] [Related]  

  • 39. New paradigms in gastrointestinal stromal tumour management.
    Blay JY
    Ann Oncol; 2009 May; 20 Suppl 1():i18-24. PubMed ID: 19430004
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Novel approaches to imatinib- and sunitinib-resistant GIST.
    Reichardt P
    Curr Oncol Rep; 2008 Jul; 10(4):344-9. PubMed ID: 18778561
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 15.